India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
December is bringing more than holiday stress—mortgage rates are climbing as the Federal Reserve delivers mixed signals and key economic reports face delays. After sharp swings in November, analysts expect rates to rise through the month, with internal disagreements among Fed members adding to the turbulence. As lenders recalibrate their expectations for early 2026, buyers and industry professionals should brace for rapid, unpredictable rate movements.
Artificial intelligence is rapidly transforming how real estate professionals work, and this week’s updates highlight just how fast the tech is evolving. Rechat’s new integration with Follow Up Boss streamlines CRM, marketing, and communication into one powerful workflow. RealScout has introduced an AI‑driven search tool built specifically for agents, delivering precise results from natural language prompts. Meanwhile, UtahRealEstate.com has launched AI voice search for consumers, offering real‑time conversational home‑finding. Together, these advancements signal a new era of efficiency and opportunity for both new and seasoned real estate professionals.
The Government Accountability Office is urging the FHFA to issue clear, updated guidance for Fannie Mae and Freddie Mac as AI‑driven tools reshape the mortgage industry. With automated valuations, underwriting systems, and algorithmic advertising carrying risks of embedded bias, regulators fear that fast‑moving proptech innovations may unintentionally reinforce past discrimination. The call for action comes as federal oversight shifts and industry professionals face growing pressure to stay compliant in an increasingly digital housing market.
Florida’s real estate and insurance sectors are undergoing major end‑of‑year shifts, from new AI oversight proposals and cooling housing markets to rising insurance premiums and transformative housing legislation. With inventory changes, pricing corrections, and new educational opportunities emerging across the state, professionals and students alike can use these insights to stay ahead in a rapidly evolving 2025–2026 landscape.
New analysis shows that eliminating property taxes in Florida—an idea promoted by Governor Ron DeSantis—could instantly raise home prices by 7 to 9 percent. While current homeowners may welcome the boost, experts warn it would worsen the state’s affordability crisis and shift tax burdens elsewhere, making it harder for future buyers and first‑time homeowners to enter the market.
Cyprus is rolling out sweeping housing and construction reforms, including fast‑track permits, incentives for affordable development, and a push for EU‑wide housing strategy. With single‑ and two‑family home approvals targeted at 40 days and apartment buildings at 80, the nation is tackling delays and boosting supply—offering insights and parallels for U.S. real estate and development professionals watching global trends.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
